Resolution of Crohn's disease and complex regional pain syndrome following treatment of paratuberculosis

1-1-2015

J Todd Kuenstner
William Chamberlin
Saleh A. Naser
University of Central Florida
Michael T. Collins
Coad Thomas Dow

See next page for additional authors

Find similar works at: https://stars.library.ucf.edu/facultybib2010

University of Central Florida Libraries http://library.ucf.edu

Recommended Citation

Kuenstner, J Todd; Chamberlin, William; Naser, Saleh A.; Collins, Michael T.; Dow, Coad Thomas; Aitken, John M.; Weg, Stuart; Telega, Grzegorz; John, Kuruvilla; Haas, David; Eckstein, Torsten M.; Kali, Maher; Welch, Christine; and Petrie, Thomas, "Resolution of Crohn's disease and complex regional pain syndrome following treatment of paratuberculosis" (2015). Faculty Bibliography 2010s. 6640.
https://stars.library.ucf.edu/facultybib2010/6640

This Article is brought to you for free and open access by the Faculty Bibliography at STARS. It has been accepted for inclusion in Faculty Bibliography 2010s by an authorized administrator of STARS. For more information, please contact lee.dotson@ucf.edu.
Resolution of Crohn’s disease and complex regional pain syndrome following treatment of paratuberculosis

J Todd Kuenstner, William Chamberlin, Saleh A Naser, Michael T Collins, Coad Thomas Dow, John M Aitken, Stuart Weg, Grzegorz Telega, Kuruvilla John, David Haas, Torsten M Eckstein, Maher Kali, Christine Welch, Thomas Petrie

J Todd Kuenstner, Department of Pathology, Charleston Area Medical Center, Charleston, WV 25304, United States
William Chamberlin, Department of Gastroenterology, Mountain View Regional Hospital, Las Cruces, NM 88011, United States
Saleh A Naser, Burnett School of Biomedical Sciences, UCF College of Medicine, Orlando, FL 32816, United States
Michael T Collins, Department of Pathobiological Sciences, the University of Wisconsin School of Veterinary Medicine, Madison, WI 53706, United States
Coad Thomas Dow, 5 Daemon Street, Eau Claire, WI 54701, United States
John M Aitken, Otakaro Pathways Ltd., 63 Bibiana Street, Christchurch 8011, New Zealand
Stuart Weg, Patients Medical, Alternative Pain Management, 500 Second Avenue Suite 900, New York City, NY 10017, United States
Grzegorz Telega, Children’s Hospital of Wisconsin, 8915 W. Connell Ave., Milwaukee, WI 53226, United States
Kuruvilla John, Department of Neurosciences, Charleston Area Medical Center, Charleston, WV 25304, United States
David Haas, Department of Chemistry, University of Charleston, Charleston, WV 25304, United States
Torsten M Eckstein, Department of Microbiology, Colorado State University, Immunology and Pathology, CO 80523, United States
Maher Kali, CAMC Clinical Trials Center, 3100 MacCorkle Avenue S.E., Suite 806, Charleston, WV 25304, United States
Christine Welch, CAMC Clinical Trials Center, Charleston, WV 25304, United States
Thomas Petrie, AVIcure Bioscience LLC, Superior Quartz Products, Bethlehem, PA 18020, United States

Author contributions: Kuenstner JT conceived of the combined UVBI and antibiotic treatment protocol and discovered the MAP infections in all of the cases; Chamberlin W and Telega G were the treating physicians for patient 1 and Chamberlin W, Weg S and John K were the treating physicians for patient 2; Naser SA, Collins MT and Aitken JM performed MAP cultures and MAP serologic assays on patients 1 through 5; Eckstein TM performed a serologic assay for leprosy on patient 2 and provided guidance on the presentation of the case reports and interpretation of the MAP literature; Haas D performed extensive analytic spectroscopic tests to confirm the chemical composition of a medication taken by patient 2; Dow CT conceived some of the theoretical basis of the study and contributed some of the references relating to human infection by MAP; Kali M and Welch C performed the statistical analysis which is a key part of the discussion; Petrie T designed and built the UVBI machine which was used to treat patients 1 and 2.

Ethics approval: Because of the devastating nature of the diseases in case 1 and case 2 and the poor record of efficacy, standard therapies were eschewed. Institutional review board approval was not sought since the law allows off label use of FDA approved drugs and also allows the administration of UVBI in New York; IRB approval is generally not required in the care of individual patients.

Informed consent: Informed consent was not sought from each of the patients in this series of case reports since each patient was treated individually and did not enroll in a formal study. Unless an operative procedure or blood transfusion is intended, physicians caring for individual patients who are not part of a formal study, do not routinely seek informed consent from their patients.

Conflict-of-interest: Kuenstner and Petrie are shareholders of AVIcure Bioscience, LLC which has a proprietary interest in the UVBI therapy described above; Naser has a proprietary interest (US Patent 7488580 B1) in a MAP test which has been licensed to Quest Diagnostics Inc. Collins is a co-inventor of a MAP serologic assay (US Patent 8158371 B1) and consultant to IDEXX Laboratories, Inc. and Zoetis Diagnostics.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: J Todd Kuenstner, MD, Department of Pathology, Charleston Area Medical Center, 3200 MacCorkle Ave. SE, Charleston, WV 25304, United States. ktodd.kuenstner@camc.org Telephone: +1-304-388-4393 Fax: +1-304-388-4352 Received: October 22, 2014 Peer-review started: October 27, 2014
INTRODUCTION

In 1998, David Relman described features of a number of poorly understood clinical syndromes that strongly indicate a microbial etiology. His list of chronic inflammatory diseases with possible microbial etiologies included sarcoidosis, inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, Wegener granulomatosis, diabetes mellitus, primary biliary cirrhosis, tropical sprue and Kawasaki disease. He noted that molecular methods of microbial identification offer an alternative when culture based microbial detection methods fail. His prediction regarding the emerging importance of molecular methods has proven correct since the combination of molecular methods of microbial detection and improvements in culture methods has led to advances in the field of paratuberculosis.

Mycobacterium avium subsp. paratuberculosis (MAP) is a bacterium that causes Johne’s disease, a chronic diarrheal wasting disease in cattle and sub-human primates and a chronic wasting disease in sheep and goats. In Johne’s disease, it is well documented that once an animal is infected with MAP, the MAP bacterium grows and multiplies inside the macrophages of the immune system. The organism is excreted in the feces, and to a lesser extent in milk. Outside the host animal, MAP multiplies poorly, but can survive for extended periods in the environment because of its resistance to heat, cold and the effect of drying. This slow-growing bacterium affects the ileum and causes diarrhea and cachexia. There are anecdotal reports of Johne’s disease in which prolonged administration of antibiotics resulted in suppression but not cure of the disease.

The viable bacterium has been found in commercially available pasteurized milk. Ellingson et al. reported that 2.7% of retail pasteurized milk samples purchased in Wisconsin, Minnesota and California contained viable MAP. Because of the presence of this organism in the food supply, it would not be surprising if MAP is widespread in the environment and the human population. The first mass screening study for evidence of MAP infection in humans was done in North India on serum, blood and stool samples submitted from patients with multiple medical conditions including diabetes, liver disorders, anemia, thyroid, tuberculosis, typhoid, abdominal disorders, inflammatory illness and ion imbalance. Singh et al. reported that 34% of 23196 serum samples had anti-MAP antibodies (a comparison with normal subjects was not included). The same study showed that 12.7% of 1246 blood samples from normal healthy individuals had IS900 PCR evidence of MAP in their blood and 8.4% of 3093 blood samples from patients with the above listed medical conditions had PCR evidence of MAP.

It has been suggested for years that there may...
be an association between Crohn’s disease (CD) and Johne’s disease. Dalziel first speculated in 1913 that chronic enteritis, now known as CD, might be caused by MAP⁴⁸ and Chiodini first reported the culturing of mycobacteria from the intestinal tissues of CD patients⁹. For many years, the data were conflicting²,¹⁰,¹¹ and the theory that MAP causes CD remains controversial¹²-¹⁴. Later on, Hermon-Taylor and others described a case of a boy with cervical lymphadenitis caused by MAP who later developed CD¹⁵. Recent studies show an increase in the detection and isolation of MAP in adult Crohn’s patients¹⁶ and in children with newly diagnosed CD¹⁷. Meta-analyses by Feller et al.¹⁸ and Abubakar et al.¹⁹ have concluded that a majority of studies on the association of MAP and CD show that most patients with CD have MAP infection. In 2004, Naser et al.²⁰ reported culturing MAP from the blood of 50% of patients with CD and this work was confirmed in four laboratories including the Centers for Disease Control and Prevention²¹,²².

In addition, a large, randomized, double-blind, placebo-controlled study from Australia showed a significant but not lasting response of individuals with CD who were treated with antibiotics against MAP²³. Apparently unaware that antibiotics fail to cure a majority of patients with Mycobacterium avium complex infection (MAC)²⁴, the authors incorrectly concluded that because they failed to cure patients, CD could not be caused by mycobacterial infection. This study and the conclusions of its authors were significantly flawed²⁵,²⁶. The editorial which accompanied the article acknowledged that, "subtherapeutic doses of rifabutin (450 mg), clarithromycin (750 mg) and clofazimine (50 mg) per day were used, whereas the optimal dose of rifabutin, clarithromycin and clofazimine for treatment of M. avium complex infections is 600 mg/d, 1000-2000 mg/d, and 100 mg/d, respectively"²⁷. A recent meta-analysis of antibiotic trials in CD conducted by Feller and coworkers concludes that a substantial benefit was evident in trials using nitromidazoles, clofazimine and ciprofloxacin and that a combination of clarithromycin and rifampycin and ciprofloxacin should be studied²⁸.

Most research attention in inflammatory bowel disease has focused on the genetics of CD rather than the association of the disease with paratuberculosis infection. However, these two areas of research are probably complementary because the genetic mutations, which have been described, may indicate increased susceptibility to MAP infection. Also in cattle, NOD2 mutations are associated with susceptibility to MAP infection²⁹, and this same mutation has been linked to patients with CD. A 2009 study from China showed that patients with another mycobacterial infection, leprosy, and patients with CD have higher rates of the NOD2, TNFSF15 and IL12B mutations than healthy controls¹⁰,¹¹. A large meta-analysis genome-wide association study concluded that there is considerable overlap between the susceptibility loci for IBD and mycobacterial infection³². In the only simulated human-challenge trial, Israeli researchers showed that fetal human small intestine explants in mice with severe combined immunodeficiency and then inoculated with MAP intraluminally, showed invasion of the goblet cells, tissue damage and inflammation³³.

In 2006, Dow postulated that MAP may be the trigger for type 1 diabetes mellitus (T1DM)³⁴ because of the association of T1DM with mutations of the SLC11a1 gene³⁵. This gene encodes a membrane protein of the lysozymes of monocytes and macrophages. Mutations in this gene have been associated with susceptibility to infectious diseases including tuberculosis and leprosy and lead to a more hospitable host environment for bacterial survival and replication³⁶. Subsequently, Sechi and others reported an association of MAP and T1DM³⁷-³⁹. Recently, Naser et al.⁴⁰ showed that there is a high degree of homology between GAD65 and Hsp65 which supports a mycobacterial role in the immune destruction of the beta cells of the pancreatic islets through molecular mimicry.

Additional findings in T1DM also present in other mycobacterial infections include elevated angiotensin converting enzyme (ACE) levels³¹,³² and elevated vascular endothelial growth factor (VEGF)³³. VEGF has been reported to be elevated in active pulmonary tuberculosis and to decline following successful treatment³⁴. Some 24.5% of patients with T1DM have a positive Saccharomyces cerevisiae Antibody (ASCA) test which is similar to the frequency of ASCA positivity in Crohn’s disease³⁵. Consumption of milk is a risk factor for the development of T1DM³⁶,³⁷.

Frau and others have also reported an association of MAP and multiple sclerosis (MS)³⁸. Consumption of milk is also a risk factor for the development of MS³⁹.

The following case reports demonstrate an association of MAP with several of the above described diseases as well as with two diseases which have not yet been linked to MAP. In addition, the diseases which were treated with anti-MAP therapy resolved.

**Assays for evidence of MAP infection**

Three assays were performed on EDTA blood samples from each patient (Figure 1). The plasma was assayed for antibodies to MAP by ELISA using culture filtrate antigens of MAP strain UCF-4 as described⁵². Peripheral blood leukocytes were harvested and used for DNA extraction followed by IS9900 PCR as described⁵¹. The remainder of the leukocytes were inoculated into BACTEC MGIT ParaTB medium with supplements but without antibiotics and incubated for 6 mo at 37 °C. After incubation, the culture pellets were harvested and subjected to DNA extraction, followed by nested IS9900 PCR as described⁵². Subcultures were done on all PCR-positive MGIT cultures to attempt recovery of MAP in pure culture.
antibody solution were added per well and plates were incubated at room temperature for 30 min. Plates were washed as before and 100 µL of room temperature 3,3′,5,5′-tetramethylbenzidine were added per well. Plates were incubated at room temperature for 10 min. The reaction was stopped by adding 100 µL of 2 mol/L sulfuric acid per well. Plates were read at 450 nm using an iMark Microplate Reader (BioRad).

**CASE REPORT**

**Case 1**

At the Children’s Hospital of Wisconsin, Dr. Grzegorz Telega began following a 9-year-old boy who was diagnosed with CD in June 2004. He initially presented in 2004 with persistent diarrhea, weight loss and unexplained fever. His linear growth had slowed considerably. Colonoscopy and upper gastrointestinal endoscopy showed multiple aphthous ulcers in the colon, terminal ileum and stomach (Figure 2) and biopsies obtained in the colon and gastric antrum contained the granulomas of CD (Figure 3). His erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) were increased.

MAP testing was performed on the patient’s blood. The initial sample showed mildly elevated antibody titers to one of the MAP antigens, p35, and after several months of incubation, MAP was grown from the patient’s blood. The second sample drawn more than 3 mo later showed greater elevations of antibodies to
both p35 and p36 antigens and also grew MAP (See Table 1 for the summary of MAP testing in this and the subsequent 4 cases). During the 3 mo between the initial and second sample, the patient’s clinical condition steadily worsened with increasing abdominal pain and frequency of diarrhea. At the time of the initial diagnosis, the patient was 4 feet 8.75 inches or in the 95th percentile in stature and weighed 71.8 pounds (75th percentile). Prior to the onset of illness, his weight had previously reached 80 pounds (90th percentile).

Initially, in August 2004, the patient received azathioprine and steroids with concurrent antibiotic therapy including clarithromycin and rifabutin, in low doses similar to those used in the Australian trial [23].

Dr. Telega, the pediatric gastroenterologist, prescribed the antibiotics and received consultative advice initially from Dr. Hermon-Taylor and later additionally from Drs. Chamberlin and Borody. The patient also took daily probiotics, which were administered at mid-day.

After 7 d of antibiotic therapy, as predicted by Dr. John Hermon-Taylor the patient developed a mild fever that lasted for several days, which Dr. Hermon-Taylor had previously observed in other patients and compared to a Jarish Herxheimer reaction. Because of an elevated ALT and AST, the azathioprine was discontinued.

Table 1  Summary of Mycobacterium avium subsp. paratuberculosis antibody, PCR and culture results for cases 1 through 5

| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
|--------|--------|--------|--------|--------|
| MAP Ab | 5/11/04 | 11/6/12 | 1/14/13 | 3/14/13 | 1/10/13 |
| p35-0.25 | ELISA S/P | ELISA S/P | ELISA S/P | ELISA S/P |
| p36-0.16 | 1.24 | 0.49 | 0.49 | 0.49 |
| MAP PCR | 5/11/04 | 11/6/12 | 1/14/13 | 3/14/13 | 1/10/13 |
| negative | negative | negative | negative | negative |
| MAP culture | 5/11/04 | 11/6/12 | 1/14/13 | 3/14/13 | 1/10/13 |
| positive | negative | negative | negative | positive |
| MAP Ab | 8/18/04 | 11/20/12 | Month/year-pending | Month/year-pending | Month/year-pending |
| p35-0.5 | ELISA S/P | ELISA S/P | ELISA S/P | ELISA S/P |
| p36-0.3 | 1.31 | 0.15 | 0.15 | 0.15 |
| MAP PCR | 8/18/04 | 11/20/12 | negative | negative | negative |
| negative | negative | negative | negative | negative |
| MAP culture | 8/18/04 | 11/20/12 | positive | positive | positive |
| positive | positive | positive | positive | positive |
| Anti-MAP therapy | therapy | therapy | therapy | therapy |
| started | started | started | started | started |
| MAP Ab | 9/20/04 | 4/17/13 | 5/17/14 | 5/17/14 | 5/17/14 |
| p35-0.33 | ELISA S/P | ELISA S/P | ELISA S/P | ELISA S/P |
| p36-0.22 | 1.20 | 1.69 | 1.69 | 1.69 |
| MAP PCR | 9/20/04 | 4/17/13 | negative | negative | negative |
| negative | negative | negative | negative | negative |
| MAP culture | 9/20/04 | 4/17/13 | positive | positive | positive |
| positive | positive | positive | positive | positive |
| MAP Ab | 7/9/07 | 5/7/14 | negative | negative | negative |
| 1.69 | ELISA S/P | ELISA S/P | ELISA S/P | ELISA S/P |
| MAP PCR | 7/9/07 | 5/7/14 | negative | negative | negative |
| negative | negative | negative | negative | negative |
| MAP culture | 7/9/07 | 5/7/14 | negative | negative | negative |
| negative | negative | negative | negative | negative |
| MAP Ab | 5/27/14 | ELISA S/P | negative | negative | negative |
| 0.67 | 0.67 | 0.67 | 0.67 | 0.67 |
| MAP PCR | 5/27/14 | negative | negative | negative | negative |
| negative | negative | negative | negative | negative |
| MAP culture | 5/27/14 | negative | negative | negative | negative |

MAP: Mycobacterium avium subsp. Paratuberculosis.

Figure 3  Biopsy from the colon showing a granuloma of Crohn’s disease.
December 2004. The patient responded favorably to the antibiotics for about 8 mo, but by June 2005, he became symptomatic and relapsed (a finding similar to that of the Australian trial). The period of relapse lasted from June 2005 to March 2006 and during this time he remained on low dose antibiotics. A colonoscopy on January 11, 2006 showed multiple aphthous ulcers in the colon and his weight on that day was 77.3 pounds (35 kg). On January 13th, a short course of prednisone was initiated at a dose of 10 mg/d. On January 15th, the dose of prednisone was increased to 20 mg/d. By February 11th, his weight was 90 pounds (41 kg).

In late 2005, in addition to receiving antibiotics, over the course of a three-month period, the patient received a total of 11 once weekly ultraviolet blood irradiation (UVBI) treatments which were performed by Dr. Mitchell Kurk at his office in Long Island, New York. A similar UVBI device has been successfully advanced through phase II clinical trials at the FDA.

In addition to UVBI therapy, on advice from experts, the doses of clarithromycin and rifabutin were increased and ciprofloxacin was added to the regimen. On January 13, 2006, the patient was started on ciprofloxacin at a dose of 125 mg taken twice per day (7 mg/kg per day) and two weeks later this dose was increased to 250 mg taken twice per day (14 mg/kg per day). On February 12, 2006, when the patient weighed 90 pounds (41 kg) the dose of clarithromycin was increased to 750 mg, 500 mg taken in the am and 250 mg taken in the pm (18 mg/kg per day) and the dose of rifabutin was increased to 150 mg in the am and 300 mg in the pm (11 mg/kg per day). In May 2006, after the patient was in clinical remission, clofazimine (an antibiotic with restricted use in the United States which is used for the treatment of leprosy and Mycobacterium avium complex) was added at a dose of 50 mg taken once daily. The clofazimine was obtained from a source in Australia.

The patient had a history of seasonal (triggered by pollen) asthma beginning at age 3 years and the last episode of asthma he has experienced was in April 2006.

These antibiotics have been used in many prior studies to treat MAP in humans. The doses in this patient were adjusted over time. He received over 4 years of continuous antibiotic therapy until January 2009. From January 2009, he was on cycled therapy of rifabutin, ciprofloxacin and clarithromycin until May 2011. The patient has been in complete remission since April 2006.

Since May 2011, he has received no medications of any type and he has been without any signs or symptoms of CD and is now 5 feet 10.5 inches and 185 pounds (84.1 kg). A follow-up blood culture for MAP in July 2007 failed to recover MAP by culture or detect MAP DNA by PCR and he tested negative for anti-MAP antibody. Currently, he has a normal blood count and is negative for inflammatory markers including ESR and CRP. A colonoscopy and upper gastrointestinal endoscopy in August, 2014 were normal. There are many reports in the literature of patients with CD who have responded favorably to antibiotic therapy.\[28,53-55\].
Case 2
In early 2012, the sibling of case 1, a 23-year-old female began experiencing symptoms initially thought to be carpal tunnel syndrome and by August 2012, developed Raynaud’s phenomenon in both hands. She had a several year history of hypothyroidism and was on thyroid hormone replacement. The symptoms of neuralgia and paresthesia progressively advanced and involved her bilateral hands, elbows, shoulders, neck, legs and feet. By the time she was seen at the Cleveland Clinic Neurological Center for Pain in late November, the physician who examined her noted Raynaud’s phenomenon in both hands and described the purple color change and cold temperature as profound.

Her workup included a normal EMG study, normal CT scan of the brain, and normal values for procalcitonin, ESR, CRP, IL-6, ASCA IgA and IgG, rheumatoid factor, ANA, SS-A/RO, SS-B/LA, SCL, RNP, SM, CCP, JO-1, Centromere antibodies, Anti-Hu TTG-IgA, lyme serology, gliadin peptide IgA and IgG, anti-endomysial IgA, serum MPA IgG, MPA IgA, MPA IgM, MPA kappa, MPA lambda, MPA kappa/lambda ratio, glutamic acid decarboxylase antibody and ganglioside antibody studies. Because of a history of travel to Guatemala 5 years prior to the onset of her illness, the patient’s blood was tested for antibody to M. leprae. The PGL-1 assay was negative. The initial diagnosis at the Cleveland Clinic was hypersensitivity syndrome and the patient was referred to the Cleveland Clinic Neurological Center for Pain where she received the diagnosis of thoracic outlet syndrome with probable evolving complex regional pain syndrome (CRPS).

Recommendations for therapy included physical therapy, muscle relaxants and gabapentin. Gabapentin at the lowest recommended dose made her very dizzy and therefore, she discontinued this medication. The patient obtained multiple sessions of physical therapy which were beneficial and engaged in gradually increasing regular exercise including walking and swimming as tolerated. In December 2012, she could only walk 300 feet or tread water wearing a floatation device for 5 min. The cause of this condition is unknown.

Due to suspicion that CRPS could be a manifestation of a MAP infection, blood samples were tested for evidence of MAP infection; the first blood sample was obtained November 6, 2012 and the second on November 20, 2012. The results of the MAP ELISA assays from both samples showed significantly elevated titers, S/P values of 1.24 and 1.31 respectively, where the positive control serum was from a veterinarian who had accidentally injected himself with the MAP vaccine. The MAP PCR tests were both negative. MAP was detected by culture from the second blood sample. There was rapid progression of clinical disease between November 6, 2012 when her MAP antibody titer was 1.24 and the organism could not be cultured while she had monocytosis and lymphocytosis and November 20, 2012 when her antibody titer increased to 1.31 and the organism could now be cultured while she no longer had monocytosis and lymphocytosis. During this two week period she developed generalized extreme hypersensitivity to minor tactile stimuli. MAP experts were consulted and appropriate antibiotics were prescribed.

Other diagnostic test results included elevated cryoglobulins of 57 (normal 0-50 ug/mL) and ACE level of 59 (normal 8-53 U/L). Cryoglobulins [57-59] and ACE [60,61] are elevated in other mycobacterial infections including tuberculosis and leprosy. Prior to the onset of disease and the initiation of therapy, the patient had persistent relative lymphocytosis and eosinophilia which was present as early as 1997. Relative lymphocytosis has been described in tuberculosis [62].

Neurologic findings are not uncommon in CD [63]. In addition, siblings of patients with CD are at much higher risk of developing CD than the general population [64].

In mid December 2012, the patient was placed on anti-MAP therapy and supplementary Vitamin A and Vitamin D similar to that administered to her brother. Her height and weight are 5 feet 9.5 inches and 150 pounds (68.2 kg), respectively and her antibiotic doses were as follows: Clarithromycin 500 mg twice daily (15 mg/kg per day), rifampin 300 mg twice daily (9 mg/kg per day), levofloxacin 500 mg per day (7 mg/kg per day) and clofazimine 100 mg 3 times per week (4 mg/kg per week). Four days after the initiation of therapy she experienced a mild fever which lasted two days. Dr. Stuart Weg performed 12 UVB treatments at weekly intervals for 3 mo from January through early April 2013. Previously, Weg speculated that CRPS is due to an infection caused by a cell wall deficient bacterium [65].

Dr. David Haas of the University of Charleston Chemistry Department, confirmed by gas chromatography, mass spectroscopy, ultraviolet absorption spectroscopy and infrared spectroscopy that the clofazimine, which was imported from India, was not a counterfeit drug.

Following the initiation of therapy, she developed mononcytosis and the relative lymphocytosis persisted. Since that time, she has shown marked clinical improvement including disappearance of the generalized hypersensitivity, disappearance of the previously grossly visible Raynaud’s phenomenon in her hands, and improved ability to perform motor skills with a reduction in reported pain. By the fall of 2014, she could swim one mile or walk five miles per day. Although her general condition has greatly improved including absence of the generalized extreme hypersensitivity, she still experiences episodes of migratory pain. With treatment of leprosy, reversal reactions and prolonged neuroalgia have been observed [66].

Six weeks after beginning the anti-MAP therapy, while still taking supplemental thyroxine, she began experiencing palpitations and it was noted that her TSH had dropped to the low normal range. On the
presumption that the palpitations indicated that her thyroid function was recovering, in January 2013, she stopped supplemental thyroxine, has not experienced symptoms of hypothyroidism, and her TSH is now in the normal range. A TSH from May 7, 2014 was 4.06 µIU/mL (reference range 0.350-5.55 µIU/mL). An ACE level from May 7, 2014 was still elevated at 58 U/L and a complete blood count from the same day was normal except for mild monocytosis of 9.3 % (reference range 0%-8%) and eosinophilia of 9.5% (reference range 0%-4%). By October 14, 2014, a complete blood count and differential were normal.

After four months of therapy (April 7, 2013), a follow-up blood culture for MAP showed a minimally decreased MAP ELISA S/P value of 1.2, the MAP PCR test was negative and MAP could not be cultured from this sample. A follow-up cryoglobulin study obtained from April 17, 2013 was negative after 4 h and positive after 72 h. In early January 2014, the patient consulted Dr. Kuruvilla John who has since that time followed her case.

Case 3
Since two siblings had evidence of MAP infections and responded to anti-MAP therapy, other relatives were tested. The paternal uncle of cases 1 and 2, who has longstanding T1DM, is also infected with MAP. In addition, the uncle was found to have elevated ASCA IgA, a serologic marker, which is present in T1DM and CD. The uncle's MAP serum antibody S/P value was 0.49 (negative). The patient has declined treatment for MAP.

Case 4
The nephew of the mother of cases 1 and 2 has lymphangiomatosis, a disease of unknown etiology. His blood showed a MAP ELISA antibody S/P value of 1.72 (exceptionally high). His MAP PCR and MAP culture results were negative. He had a very elevated VEGF of 506 pg/mL (reference range of 31-86 pg/mL), mild monocytosis of 992 (reference range of 200-950 cells/µL) and a normal neutrophin test, ASCA IgA and IgG, and ACE tests. The MAP ELISA study, VEGF and monocytosis in this case suggest a possible mycobacterial causation of lymphangiomatosis and further study is indicated.

Case 5
The father of cases 1 and 2 was tested for MAP infection. After 6 mo of incubation, MAP was grown from his blood. His MAP PCR on PBMCs was negative and his MAP ELISA antibody S/P value was 0.15 (negative). He is healthy but suffered from seasonal asthma (triggered by pollen) at age 12 years and also while living in Germany from 1986 to 1989. In addition, he has rosacea, which was diagnosed by clinical signs and a skin biopsy showing non-caseating granulomas. This condition is treated with a topical ointment containing azelaic acid. In 2004, his blood was found positive for antibodies to p35 and p36 MAP antigens.

Because of the devastating nature of the diseases in case 1 and case 2 and the poor record of efficacy, standard therapies were eschewed. Institutional review board (IRB) approval was not sought since the law allows off label use of FDA approved drugs and also allows the administration of UVBI in New York. IRB approval is generally not required in the care of individual patients. In cases 1 through 3, infectious disease specialists were consulted and informed about the elevated MAP ELISA antibody titers and/or positive MAP cultures but declined to make recommendations regarding therapy.

Additional family members were tested for evidence of MAP infection as well. The mother of case 1 and case 2 was negative for MAP by PCR on PBMC and culture, and had an ELISA S/P of 0.08 (negative). The brother of case 1 and case 2 had a negative MAP PCR and negative culture and ELISA S/P of 0.59 (slightly elevated). The maternal grandfather of case 1 and case 2 had a negative MAP PCR on PBMCs and negative culture and an ELISA S/P of 0.13 (negative). The maternal grandmother (with hypothyroidism) of case 1 and case 2 had a negative MAP PCR on PBMCs and negative culture and an ELISA S/P of 0.0 (negative).

The families of both parents of case 1 and case 2 have a history of susceptibility to mycobacterial infection. Figure 4 which is a family pedigree summarizing the cases and the mycobacterial infection and other disease history in other members.

**DISCUSSION**

The presence of viable MAP in the blood of a majority of CD patients is an important finding which has been previously reported by Naser[20,22]. Some observers ascribe this phenomenon to the "leaky bowel" resulting from mucosal disruption in CD[67]. In case 1, the recovery of the viable organism in the setting of two diseases and the failure to recover the viable organism in the absence of these two diseases argues in favor of a pathogenic role of MAP in these patients. Similarly, in case 2, the recovery of the viable organism in the setting of two other diseases and the failure to recover the organism in the absence of these two other diseases also argues in favor of a pathogenic role of MAP. Furthermore, the recovery of the viable organism in case 2 in which the patient suffered from CRPS cannot be explained by the leaky bowel hypothesis since this patient has not experienced bowel related symptoms. In addition, a pathogenic role of MAP in the human host is likely, considering the zoonotic capacity of slow-growing mycobacteria and because this organism is an obligate pathogen, i.e., one which does not propagate in the environment[68].
A second possible interpretation of the findings in these case reports is that the diseases were not caused by MAP and went into remission spontaneously. In the consideration of the probable events in case 1 and case 2, the percentage of patients who experience long-term remissions in CD, CRPS, hypothyroidism and Raynaud’s phenomenon is 10%[60], 74%[70], 62%[71], and 64%[72], respectively. With the assumption that case 1 and case 2 resolved spontaneously, the outcome follows the likelihood function. The probability of spontaneous resolution in case 1 is 0.10 and in case 2 is 0.30 (0.74 x 0.62 x 0.64 = 0.30) and the probability of spontaneous resolution in both patients is 0.10 x 0.30 or 0.03 which is very unlikely. Controlled clinical trials of anti-MAP therapy are necessary to determine whether these case reports are reproducible. Clinical trials have been designed and funding is being sought.

A third possible interpretation of the recovery of MAP from the blood samples in case 1 and in case 2, is that the MAP organism is a contaminant from specimen processing. This interpretation is unlikely since in both cases there are increased antibodies directed against MAP indicating a host response to the organism. The presence of elevated serologic markers which are associated with mycobacterial infection, including CRP in case 1 and ACE in case 2, also weighs against this possibility.

We believe that the profound long lasting remission in case 1 resulted from anti-MAP therapy and is unlikely due to steroid administration, since such remissions rarely result from steroid administration alone. Based on these anecdotal reports, three additional cases of children with CD and MAP infection treated successfully with combination anti-MAP antibiotics and UVBI (personal communication), open label trials in CD, and controlled trials in MAC infection, we recommend the use of three antibiotics including clarithromycin, rifampin and levofloxacin (at 15, 9 and 7, respectively, mg/kg per day) for at least two years in combination with periodic UVBI (if available). However, at this time, the optimal antibiotic combination is unknown.

In cases 1 and 2, the rapid progression of the disease accompanied by an increase in antibodies to MAP antigens between the first two specimens may mirror Johne’s disease in dairy cattle in which the progression in the severity of disease and the degree of mycobacterial colonization coincides with a switch from the TH1 to TH2 type immune response[23].

The presence of the viable bacterium in the blood of an apparently healthy host (case 5) is an interesting finding. Apparently healthy individuals may have less virulent forms of disease such as transient childhood asthma or rosacea as noted in case 5. In addition, if MAP-infected people are followed over a long enough period of time, some may eventually develop one of the diseases traditionally considered autoimmune.

It would not be surprising if there is a population of individuals who are MAP-infected but never develop disease. Mycobacterium tuberculosis, causes active disease in only 10% of infected humans[74]. A similar situation probably pertains to human paratuberculosis, i.e., most MAP-infected individuals may never develop disease. Clinically normal cattle with known MAP infection are common suggesting a parallel in the human population[75].

Any theory of causation of the autoimmune diseases must explain two consistent observations for most of these diseases: (1) the north-south gradient in geographical distribution of the disease (in the northern hemisphere)[76], and (2) the predominant female to male ratio in most of these diseases. The first observation is concordant with the worldwide distribution of Johne’s disease[77], the lower levels of Vitamin D in the human host at northern latitudes[78] and the role of Vitamin D in the clinical course of patients with CD and T1DM[79,80]. A possible explanation for the second observation includes reduced host immunity due to the effects of estradiol and/or progesterone[81-83]. Future work may shed light on the immunology of gender differences with these diseases.

Because of the known risk of disease progression in CD from birth control medication, women who have been diagnosed and treated for a MAP infection should consider non-hormonal birth control methods.

The optimal hosts for MAP are ruminants; cattle, sheep, and deer, in which, a higher burden of bacteria are generally found than in humans. These animals have a higher body temperature than humans ranging from 100.4 to 102.8, 100.9 to 103.8 to 104 F, for cattle, sheep and deer, respectively[84,85]. These differences in body temperature suggest that the growth of MAP in laboratory culture may be accelerated by raising the incubation temperature to 104 F. Further investigation of this issue is warranted.

If controlled trials of MAP related illnesses confirm the findings of these case reports and the autoimmune diseases can be cured, because the bacterium is present in the food supply, will treated patients redevelop disease on re-exposure to the organism? The precautionary principle should apply and improved food safety and public health measures are necessary to limit human exposure to MAP. Until improved measures are in place, treated and cured patients should probably avoid known sources of MAP which include pasteurized milk and milk products such as yoghurt, cheese and ice cream and undercooked beef.

Open label trials of long-term antibiotic therapy in CD have a significant relapse rate. Adjunctive therapy such as UVBI combined with appropriate antibiotics may be a way to improve therapeutic outcomes. UVBI was developed by Knott[86]. In his article on the development of ultraviolet blood irradiation, he refers to the work of European investigators who “believed that most of the systemic reactions observed following exposure of the skin to ultraviolet rays were due to the influence of the rays upon the blood”[86]. Knott was most likely aware of the work of Finsen who received the Nobel Prize in 1903, for his work showing
the beneficial effects of ultraviolet treatments of the skin in patients with lupus vulgaris, i.e., tuberculosis of the skin[87]. The Knott device was used for the treatment of many infections[88-90], and while exact figures are unavailable, probably thousands of patients were treated with this therapy throughout the United States. Several studies[91,92] as well as three controlled trials from Russia have shown beneficial effects in the treatment of tuberculosis[93-95]. Because the Knott hemo-irradiator predated the advent of the FDA, this device was never FDA approved. However, in recent years, UVBI was advanced successfully through phase II clinical trials for the treatment of hepatitis C infection.

Various studies on UVBI that may explain the benefit of this therapy include the following. Ultraviolet light in the C region (UVC) inactivates bacterial and viral pathogens, present in the blood, which is irradiated. In the case of bacteria and DNA viruses, UVC induces the formation of thymine-thymine dimers, which prevents replication[96]. In the case of RNA viruses, UVC induces the formation of uracil-uracil dimers which also prevents replication[97]. Bacteria including Mycobacterium tuberculosis have UV repair mechanisms and normal lymphocytes also have UV repair mechanisms[98,99].

Because only 200 cc of blood in an average adult (or 4% of the total 5.0 liter blood volume) is treated during a single session, factors other than pathogen inactivation are likely to explain the potential benefit. Ultraviolet light shined on murine fibroblasts results in the formation of hydrogen peroxide and hydroxyl radicals which are also bactericidal and virucidal[100]. Ultraviolet light in the A region and at higher doses and exposure durations causes immune suppression, but ultraviolet light in the B (UVB) region and UVC have been shown to stimulate dendritic cells[101-103]. Hemoglobin which has been irradiated with UVB and UVC wavelengths exhibits fluorescence[104] and the wavelength of light which is emitted, 365 nm, causes the formation of DNA or RNA adducts in riboflavin and other chromophores and these adducts are bactericidal and virucidal[105]. It is now known that in spite of long term treatment of tuberculosis by antibiotics, there are persisters, which are not killed by the drugs[106,107]. Also Mycobacterium avium complex organisms can resist the bactericidal activity of clarithromycin within the phagosomes of macrophages[108]. Viable MAP organisms which have survived the antibiotics by either of these routes and which are within macrophages may not survive ultraviolet irradiation[109]. An in-vitro study showed that monocytes which are irradiated with UVB and then infected with Mycobacterium avium intracellulare (MAI) organisms, efficiently inhibit the intracellular replication of MAI[109]. The authors in this work speculated that the intracellular inhibition of MAI replication in the UV treated macrophages may be due to the induction of intracellular vitamin D production by the UVB.

Vitamin D has been shown to play an important role in the host immune response to mycobacterial infection[110]. Vitamins A and D have been shown to inhibit the growth of MAP in vitro[111]. Vitamin D has also been shown to reduce the proliferation of M. tuberculosis in macrophages[112]. Activated dendritic cells are known to produce Vitamin D[113] and Vitamin D induces the intracellular production of cathelicidin, which is an antimicrobial protein[114]. High levels of Vitamin D have been correlated with a reduced risk of developing multiple sclerosis, and Vitamin D intake is inversely associated with rheumatoid arthritis (another autoimmune condition) and the severity of this latter disease also correlates with Vitamin D levels[115].

Finally, many types of cells including leukocytes and, in particular, monocytes, exposed to ultraviolet light secrete heat shock proteins and these proteins play an important role in the response to infection[116-118].

A small open label trial of UVBI in 4 patients with severe Raynaud’s syndrome showed clinical improvement that lasted for 3 mo in all of the patients and a reduction of mycobacterial heat shock protein antibodies in one of the patients[118].

These case reports support a pathogenic role of MAP in humans. Large controlled trials are indicated for many of the autoimmune diseases associated with MAP infection including CD, T1DM, MS and CRPS using anti-MAP therapy combined with UVBI (perhaps substituting ethambutol for ciprofloxacin)[119] in one arm and combination infliximab and azathioprine in the control arm to determine whether properly dosed anti-MAP therapy is more effective than currently available therapies. RedHill Biopharma Ltd., Tel Aviv, Israel, has initiated phase III clinical trials in Europe and North America to treat CD and MS using a combination therapy of clarithromycin, rifabutin and clofazimine[120], MAP prevalence studies are indicated in lymphangiomatosis, ankylosing spondylitis, rheumatoid arthritis, hypothyroidism, hyperthyroidism, adrenal insufficiency, systemic sclerosis, Sjogren syndrome, systemic lupus erythematosus, dermatomyositis, psoriasis, sarcoidosis, celiac disease, rosacea, asthma, fibromyalgia, amyotrophic lateral sclerosis, myasthenia gravis, Parkinson’s disease and Alzheimer’s disease.

The results of therapeutic trials should be evaluated with consideration of the success rate in treating Mycobacterium avium complex infections, a mere 42%[27] and that the treatment of Mycobacterium leprae is associated with an absolute relapse rate of 3% and that relapses may occur more than 10 years after multiple drug therapy has concluded[121].

Researchers who explore the role of MAP in the autoimmune diseases should be aware that our current diagnostic tests are crude. The ELISA for serum antibodies to MAP[46] was adapted from the cattle assay which has a sensitivity of only 30% to 40% in cattle which are known to be MAP-infected[122]. The suboptimal sensitivity and the variation between current serologic assays for MAP make the diagnosis
of MAP infection difficult. However, in the presence of otherwise unexplained autoimmune disease, the occurrence of positive blood cultures for MAP should be a significant finding.

Furthermore, pre-existing therapies for these conditions may hinder culture recovery methods. Many of the currently used immunomodulators have demonstrated bacteriostatic effects on MAP in-vitro[123,124]. When possible, MAP diagnostic testing should be conducted on newly diagnosed patients prior to instituting immunosuppressive therapies which can inhibit the growth of MAP in cultures. While the blood culture method of Naser has been a great advance in the field of human paratuberculosis research, it is positive in 55% of patients with inflammatory bowel disease and in 22% of non-inflammatory bowel disease patients[121], and therefore cannot by itself serve as a discriminator for the presence or absence of disease. Concurrent detection of antibodies directed at MAP will probably be helpful in this regard[50]. MAP cultures should be performed in laboratories with expertise. Parrish et al[125] failed to replicate the blood culture study of Naser et al, but their method did not include egg yolk in the medium (regarded by many as vital for MAP growth) and the cultures were only held for 18 wk (MAP cultures for humans are usually held for at least 6 mo and up to one year).

The current MAP ELISA reacts to both host IgM and IgG. Modifying the assay into its isotype components, i.e., IgM and IgG, may permit a better determination of whether the host response reflects active disease or remote exposure. Further research is necessary in this area.

Should MAP be proven to cause many of the autoimmune diseases, a potential role in carcinogenesis should be explored. *Helicobacter pylori* is now recognized as playing a major role in the pathogenesis of primary gastric MALT lymphoma and gastric carcinoma[123]. CD patients are known to have increased risk of bowel cancer and lymphoma. Whether this increased risk is due to the immunosuppressive therapies used in this disease or due to infection by MAP is unknown and should be investigated further[127]. In summary, much more must be learned about this elusive and enigmatic organism and about the human diseases with which it is associated.

**REFERENCES**

1. Relman DA. Detection and identification of previously unrecognized microbial pathogens. *Emerg Infect Dis* 1998; 4: 382-389 [PMID: 9716951 DOI: 10.3201/eid0403.980310]
2. Chiiodini RJ, Van Kuuringen HJ, Merkal RS. Ruminant paratuberculosis (Johne’s disease): the current status and future prospects. *Cornell Vet* 1984; 74: 218-262 [PMID: 6375961]
3. McClure HM, Chiiodini RJ, Anderson DC, Swenson RB, Thayer WR, Coutu JA. Mycobacterium paratuberculosis infection in a colony of stump-tailed macaques (Macaca arctoides). *J Infect Dis* 1987; 155: 1011-1019 [PMID: 3559275]
4. St-Jean G, Jernigan AD. Treatment of Mycobacterium paratuberculosis infection in ruminants. *Vet Clin North Am Food Anim Pract* 1991; 7: 793-804 [PMID: 1760762]
5. Grant IR, Ball HJ, Rowe MT. Incidence of Mycobacterium paratuberculosis in bulk raw and commercially pasteurized cows’ milk from approved dairy processing establishments in the United Kingdom. *Appl Environ Microbiol* 2002; 68: 2428-2435 [PMID: 11976118]
6. Ellingon JL, Anderson JL, Kozickowski JJ, Radcliff RP, Sloan SJ, Allen SE, Sullivan NM. Detection of viable Mycobacterium avium subsp. paratuberculosis in retail pasteurized whole milk by two culture methods and PCR. *J Food Prot* 2005; 68: 966-972 [PMID: 15895728]
7. Singh SV, Kumar N, Sohal JS, Singh AV, Singh PK, Agrawal ND, Gupta S, Chaubey KY, Deb R, Dhaba K, Rawat KD. First mass screening of the human population to estimate the bio-load of Mycobacterium avium subsp paratuberculosis in North...
India. *J Pub Health Epidemiol* 2014; 6: 20-29 [DOI: 10.5897/JPHE2013.03564]

Dalziel TK. Chronic interstitial enteritis. *Br Med J* 1913; 2:

Chiiodini RJ, Van Kuiningen HJ, Merkal RS, Thayer WR, Couta JA. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease. *J Clin Microbiol* 1984; 20: 966-971 [PMID: 6511878]

Mendoza JL, Lana R, Diaz-Rubio M. Mycobacterium avium subspecies paratuberculosis and its relationship with Crohn's disease. *World J Gastroenterol* 2009; 15: 417-422 [PMID: 19152445 DOI: 10.3780/j.wjg.v15.i17]

Chiappini E, de Martino M, Mangiantini F, Lionetti P. Crohn's disease and mycobacterial infection in children: an intriguing relationship. *J Pediatr Gastroenter Nutr* 2009; 49: 550-558 [PMID: 19680150 DOI: 10.1097/MPG.0b013e3181f0908]

Cohen RD. Mycobacterium in Crohn's: something to ruminate about? *Gastroenterology* 2005; 128: 2167-2168 [PMID: 15940650 DOI: 10.1053/j.gastro.2005.02.069]

Shanahan F, O'Mahony J. The mycobacteria story in Crohn's disease. *Am J Gastroenterol* 2000; 105: 1537-1538 [PMID: 15984977]

Kuensten JT. Mycobacterium avium subspecies paratuberculosis: a human pathogen causing most cases of Crohn's disease. *Am J Gastroenterol* 2006; 101: 1157-1158; author reply 1158 [PMID: 16696794]

Hermon-Taylor J, Barnes N, Clarke F, Finlayson C. Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease. *BMJ* 1998; 316: 449-453 [PMID: 9492675]

Sechi LA, Scann A, Mollicotti P, Camsa S, Mura M, Detti G, Fadda G, Zanetti S. Detection and Isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn's disease in Sardinia. *Am J Gastroenterol* 2005; 100: 1529-1536 [PMID: 15984976]

Kirkwood CD, Wagner J, Boniface K, Vaughan J, Michalski WP, Catto-Smith AG, Cameron DJ, Bishop RF. Mycobacterium avium subspecies paratuberculosis in children with early-onset Crohn's disease. *Inflamm Bowel Dis* 2009; 15: 1643-1655 [PMID: 19462429 DOI: 10.1002/ibd.20097]

Feller M, Huwiler K, Stephan R, Alptekin E, Shang A, Furrer H, Pfäffler GE, Jenni T, Baumgartner A, Egger M. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a follow-up blind multi center investigation. *World J Gastroenterol* 2007; 13: 417-4176 [PMID: 17983825]

Peyrin-Biroulet L, Neut C, Colombel JF. Antimycobacterial therapy in Crohn's disease: game over? *Gastroenterology* 2007; 134: 2594-2598 [PMID: 17570230]

Feller M, Huwiler K, Schöpfer A, Shang A, Furrer H, Egger M. Long-term antimicrobial treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. *Clin Infect Dis* 2010; 50: 473-480 [PMID: 20067425]

Pinedo PJ, Baugelt CD, Donovan GA, Melendez P, Morel L, Wu R, Langae B, Tae DO. Association between CARD15/NOD2 gene polymorphisms and paratuberculosis infection in cattle. *Vet Microbiol* 2009; 134: 346-352 [PMID: 19266647]

Zhang FR, Huang W, Chen SM, Sun LD, Liu H, Li Y, Cui Y, Yan XX, Wang Y, Yang L, Chu TS, Zhang C, Zhang L, Han JW, Yu GQ, Quan C, Yu XY, Zhang Z, Shi BQ, Zhang LH, Cheng H, Wang CY, Lin Y, Zheng HF, Xu XA, Zou XB, Wang Q, Long H, Sun YP, Cheng YL, Tian HQ, Zhou FS, Liu HX, Lu WS, He SM, Du WL, Shen M, Jin QY, Wang Y, Low HQ, Erwin T, Wang NY, Li JY, Xiao X, Jiao YL, Mao LG, Yin G, Jiang ZX, Wang XD, Yu JP, Hu ZH, Gong CH, Liu YQ, Liu YR, Wang DM, Wei D, Liu JX, Cao WK, Cao HZ, Li YB, Yan WG, Wei SY, Wang KJ, Bibbard ML, Yang S, Zhang XJ, Liu JJ. Genomewide association study of leprosy. *N Engl J Med* 2009; 361: 2609-2618 [PMID: 20018961 DOI: 10.1056/NEJMoa0903753]

Schurr E, Gros P. A common genetic fingerprint in leprosy and Crohn's disease? *N Engl J Med* 2009; 361: 2666-2668

Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Ceyleny I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Aminnejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balchunis T, Bampton PA, Bittar A, Boucher G, Brand S, Büring C, Cohain A, Cichon S, D’Amato M, De Jong D, Devaneau KL, Dubinsky M, Edwards C, Ellingham D, Ferguson LR, Franchimont D, Fransen K, Garry R, Georges M, Gieger C, Glis J, Haritunians T, Hart A, Hawkey C, Hedi M, Hu X, Karlsen TH, Kupcinets L, Kugathasan S, Latino A, Laukens D, Lawrence IC, Lee WS, Louis E, Mahy G, Mansfield J, Morgan AR, Movat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter J, Russell RK, Sanderson JD, Sari S, Satsangi J, Schreiber S, Simmers LA, Sventoartitej J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xiao RJ, Reissig S, Zhang B, Zhang CK, Zhao H. International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annesee V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H. Promoter polymorphism of SLC11A1 (formerly NRAMP1) confers risk for inflammatory bowel disease. *Nature* 2012; 491: 119-124 [PMID: 23128233 DOI: 10.1038/nature11582]

Golan L. Liver: the liver functions with normalcy in the face of chronic disease. *Clin Infect Dis* 2009; 49: 231-236 [PMID: 19498712]

Takahashi K, Satoh J, Koizuma Y, Negro K, Hirai M, Hinokio Y, Kinosuchi Y, Suzaki S, Matsaura N, Shimosegawa T, Oka Y. Promoter polymorphism of SLC11A1 (formerly NRAMP1) gene polymorphisms associated with pediatric tuberculosis in China. *Clin Infect Dis* 2009; 48: 733-738 [PMID: 19193106 DOI: 10.1097/INF00009073034]
Kuenstner JT et al. Diagnosis and treatment of paraburcolysis

37 Sechi LA, Rosu V, Pacifico A, Fadda G, Ahmed N, Zanetti S. Humoral immune responses of type 1 diabetes patients to Mycobacterium avium subsp. paraburcolysis lend support to the infectious trigger hypothesis. Clin Vaccine Immunol 2008; 15: 320-326 [PMID: 18077912]

38 Rosu V, Ahmed N, Paccagnini D, Gerlach G, Fadda G, Hasnain SE, Zanetti S, Sechi LA. Specific immunooassays confirm association of Mycobacterium avium Subsp. paraburcolysis with type-1 but not type-2 diabetes mellitus. PLoS One 2009; 4: e3438 [PMID: 19204799 DOI: 10.1371/journal.pone.0003436]

39 Bitti ML, Masala S, Capasso F, Rapini N, Piccinini S, Angelini F, Pierantozzi A, Lidano R, Pietrosanti S, Paccagnini D, Sechi LA. Mycobacterium avium avium subsp. paraburcolysis in an Italian cohort of type 1 diabetes pediatric patients. Clin Dev Immunol 2012; 2012: 785262 [PMID: 22844325 DOI: 10.11520/2012/785262]

40 Naser SA, Thanigachalam S, Dow CT, Collins MT. Exploring the role of Mycobacterium avium subspecies paraburcolysis in the pathogenesis of type 1 diabetes mellitus: a pilot study. Gut Pathog 2013; 5: 14 [PMID: 23759115 DOI: 10.1186/1757-4749-5-14]

41 Scherhagener G, Schwarzer C, Kuzmits R, Müller MM, Klemen U, Freyler H. Increased angiotensin-converting enzyme activities in diabetes mellitus: analysis of diabetes type, state of metabolic control and occurrence of diabetic vascular disease. J Clin Pathol 1984; 37: 307-312 [PMID: 6321559]

42 Van Dyk DJ, Erman A, Erman T, Chen-Gal B, Sulkis J, Boner G. Increased serum angiotensin converting enzyme activity in type 1 insulin-dependent diabetes mellitus: its relation to metabolic control and diabetic complications. Eur J Clin Invest 1994; 24: 463-467 [PMID: 7957562]

43 Chiarelli F, Spagnoli A, Baszani C, Tumini S, Mezzetti A, Cipolloni F, Cuccurullo F, Morgese G, Verrotti A. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 2000; 17: 650-656 [PMID: 11051284]

44 Alatas F, Alatas O, Metintas M, Ozarslan A, Erginel S, Yildirim H. Vascular endothelial growth factor levels in active pulmonary tuberculosis. Chest 2004; 125: 2156-2159 [PMID: 15189936]

45 Sakly W, Manaki A, Sakly N, Thabet Y, Achorou A, Ghedira B. Anti-Saccharomyces cerevisiae antibodies are frequent in type 1 diabetes pediatric patients. Clin Vaccine Immunol 2010; 17: 92-97 [PMID: 20866042]

46 Gimeno SG, de Souza JM. IDDM and milk consumption. A case-control study in São Paulo, Brazil. Diabetes Care 1997; 20: 1256-1260 [PMID: 9250450]

47 Virtanen SM, Lääri E, Hyypänä E, Reijonen H, Räsänen L, Aro A, Kuopio L, Ilonen J, Akerblom HK. Cow’s milk consumption, HLA-DQ and Type 1 diabetes mellitus. Am J Epidemiol 1993; 138: 590-596 [PMID: 7707472]

48 Fraus J, Cozzo D, Coghe G, Lorencce F, Fenu G, Melis M, Paccagnini D, Sardu C, Murro MR, Tranquilli S, Marrosu MG, Sechi LA. Cocco E. Mycobacterium avium subsp. paraburcolysis and multiple sclerosis in Sardinian patients: epidemiological and clinical studies. Multi Scler 2013; 19: 1437-1442 [PMID: 23439580 DOI: 10.1177/1352458513477926]

49 Malosse D, Perron H, Sasoa A, Seigneurin JM. Correlation between milk and dairy product consumption and multiple sclerosis prevalence: a worldwide study. Neuroepidemiology 1992; 11: 304-312 [PMID: 1291895]

50 Shin AR, Kim HJ, Cho SN, Collins MT, Manning EJ, Naser SA, et al. Anti-S. Humoral immune responses of type 1 diabetes patients to Mycobacterium avium Subsp. paraburcolysis human isolates to sera from Crohn’s disease patients. FEMS Immunol Med Microbiol 2010; 58: 128-137 [PMID: 19878316 DOI: 10.1111/ j.1574-695X.2009.00617.x]

51 Bull T, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, Neild P, Rhodes G, Pickup R, Hermon-Taylor J. Detection and verification of Mycobacterium avium subsp. paraburcolysis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn’s disease. J Clin Microbiol 2003; 41: 2915-2923 [PMID: 12843021]
trial of vitamin D supplementation in patients with pulmonary tuberculosis. *BMC Infect Dis* 2013; 13: 22 [PMID: 23331510 DOI: 10.1186/1471-2334-13-22]

111 Greenstein RJ, Su L, Brown ST. Vitamins A &amp; D inhibit the growth of mycobacteria in radiometric culture. *PLoS One* 2012; 7: e29631 [PMID: 23331510 DOI: 10.1186/1471-2334-13-22]

112 Hewison M. An update on vitamin D and human immunity. *Clin Endocrinol (Oxf)* 2012; 76: 315-325 [PMID: 21995874 DOI: 10.1111/j.1365-2265.2011.04261.x]

113 Cutolo M, Otsa K. Review: vitamin D, immunity and lupus. *Lupus* 2008; 17: 6-10 [PMID: 18089676]

114 Chun RF, Lauridsen AL, Suon L, Zella LA, Pike JW, Modlin RL, Martineau AR, Wilkinson RJ, Adams J, Hewison M. Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1,25-dihydroxyvitamin D. *J Clin Endocrinol Metab* 2010; 95: 3368-3376 [PMID: 20427486 DOI: 10.1210/jc.2010-0195]

115 Agnew LL. Measuring intracellular hsp70 in leukocytes by flow cytometry. *Curr Protoc Toxicol* 2011; Chapter 2: Unit2.21 [PMID: 21818752 DOI: 10.1002/0471140856.bx0221s49]

116 Matsuda M, Hoshino T, Yamashita Y, Tanaka K, Maji D, Sato K, Adachi H, Sobue G, Ihn H, Funasaka Y, Mizushima T. Prevention of UVB radiation-induced epidermal damage by expression of heat shock protein 70. *J Biol Chem* 2010; 285: 5848-5858 [PMID: 20018845 DOI: 10.1074/jbc.M109.063453]

117 Pockley AG. Heat shock proteins as regulators of the immune response. *Lancet* 2003; 362: 469-476 [PMID: 12927347]

118 Cooke ED, Pockley AG, Tucker AT, Kirby JD, Bolton AE. Treatment of severe Raynaud's syndrome by injection of autologous blood pretreated by heating, ozonation and exposure to ultraviolet light (H-O-U) therapy. *Int Angiol* 1997; 16: 250-254 [PMID: 9543222]

119 Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Oliver K, Ruoso S, von Reyn CF, Wallace RJ, Winthrop K. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007; 175: 367-416 [PMID: 17277290]

120 Redhill Biopharma. Available from: URL: http://www.redhillbio.com

121 Cellona RV, Balagon MF, dela Cruz EC, Burgos JA, Abalos RM, Walsh GP, Topolski R, Gelber RH, Walsh DS. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. *Int J Lepr Other Mycobact Dis* 2003; 71: 308-319 [PMID: 14763888]

122 Clark DL, Koziczkowski JJ, Radcliff RP, Carlson RA, Ellingson JL. Detection of Mycobacterium aviun subspecies paratuberculosis: comparing fecal culture versus serum enzyme-linked immunosorbent assay and direct fecal polymerase chain reaction. *J Dairy Sci* 2008; 91: 2620-2627 [PMID: 18565921 DOI: 10.3168/jds.2007-0902]

123 Greenstein RJ, Su L, Haroutunian V, Shahidi A, Brown ST. On the action of methotrexate and 6-mercaptopurine on M. aviun subspecies paratuberculosis. *PLoS One* 2007; 2: e161 [PMID: 17252054 DOI: 10.1371/journal.pone.0000161]

124 Shin SJ, Collins MT. Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. *Antiinmicrob Agents Chemother* 2008; 52: 418-426 [PMID: 18070971]

125 Parrish NM, Radcliff RP, Brey BJ, Anderson JL, Clark DL, Koziczkowski JJ, Ko CG, Goldberg ND, Brinker DA, Carlson RA, Dick JD, Ellingson JL. Absence of mycobacterium aviun subsp. paratuberculosis in Crohn's patients. *Inflamm Bowel Dis* 2009; 15: 558-565 [PMID: 19058231 DOI: 10.1002/ibd20799]

126 Copie-Bergman C, Locher C, Levy M, Chaumette MT, Haioun C, Delfau-Larue MH, Leroy K, Gaulard P, Delchier JC. Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? *Ann Oncol* 2005; 16: 1232-1236 [PMID: 15890667]

127 Hemminki K, Li X, Sundquist J, Sundquist K. Cancer risks in Crohn disease patients. *Ann Oncol* 2009; 20: 574-580 [PMID: 18765463 DOI: 10.1093/annonc/mdn595]
